Skip to content
Aminoscope
Head-to-head

Ashwagandha vs Kanna

Two herbs sold for the same feeling, with completely different risk profiles — one works on cortisol, the other on the serotonin transporter.

By Julian RothResearch & dataUpdated October 2026

Short answer

Neither ashwagandha nor kanna needs a prescription, and both have human data, so the goal decides it. Ashwagandha is marketed for stress, sleep and testosterone; kanna is the choice for readers interested in mood, stress and anxiety, focus and social ease.

Ashwagandha

Withania somnifera

Clinical data

The best-studied adaptogen: multiple placebo-controlled RCTs for lowering stress and cortisol, decent sleep data, and a modest testosterone signal — with a rare but real liver-injury caveat.

Full Ashwagandha evidence review

Kanna

Sceletium tortuosum, Mesembryanthemum tortuosum, Zembrin, mesembrine

Clinical data

The researched extract is a genuine dual serotonin-reuptake and PDE4 inhibitor with a real human imaging trial — which is also why it is the rare supplement whose mechanism argues for caution alongside SSRIs. The efficacy base is one branded extract in small acute trials, the best anxiety study was null in the first of its two arms, and a 2026 review calls the literature mixed.

Full Kanna evidence review

Ashwagandha vs Kanna: head to head

FDA status / approved use

Ashwagandha

Sold as an herbal supplement

Kanna

Sold without a prescription as a mood supplement
Marketed for

Ashwagandha

Stress, sleep, testosterone

Kanna

Mood, stress and anxiety, focus, social ease
Outcome areas

Ashwagandha

Mood / anxiety / stress; Sleep; Testosterone / male hormones

Kanna

Mood / anxiety / stress; Cognitive function / memory
Evidence grade

Ashwagandha

Clinical data

Kanna

Clinical data
How it works

Ashwagandha

Hormonal

Kanna

Inhibits serotonin reuptake and PDE4, an SSRI-like mechanism
Route and dosing

Ashwagandha

Oral standardized root extract, often taken twice daily with food

Kanna

Standardized extract, 25 mg in trials; also sold as a vape
Headline human result

Ashwagandha

Serum cortisol fell roughly a quarter to a third, with lower perceived stress, vs placebo in a 60-day 2012 RCT of 64 adults

Kanna

A single 25 mg dose showed no effect in one study and lower pre-stress anxiety in a second (2020)
Strongest evidence

Ashwagandha

RCT, Indian J Psychol Med 2012Ashwagandha evidence reviewPubMed 23439798

Kanna

Amygdala fMRI RCT, Neuropsychopharmacology 2013Kanna evidence reviewPubMed 23903032
Key safety signal

Ashwagandha

Rare but documented liver injury, usually 2 to 12 weeks after starting

Kanna

Serotonin toxicity risk when combined with SSRIs, SNRIs, MAOIs or other serotonergic drugs
How it is obtained

Ashwagandha

Over the counter as a dietary supplement

Kanna

Over the counter as a dietary supplement

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

The mechanisms are what separate these, not the marketing. Ashwagandha's case rests on several small placebo-controlled trials reporting reduced perceived stress and lower cortisol, a reasonably replicated if modest picture, with the real safety signal being rare but documented liver injury. Kanna is pharmacologically the more interesting and the more cautious buy: its standardized extract is a dual serotonin-reuptake and PDE4 inhibitor, demonstrated acutely in a human amygdala imaging trial, which means it shares a mechanism with SSRI antidepressants and should not be combined with serotonergic medication. Its efficacy evidence is thinner than ashwagandha's — one branded extract, small acute studies, and an anxiety trial whose first of two arms found nothing.

Ashwagandha fits if

You want the option with more replication behind the stress claim, and you will watch for the liver signal rather than assume a herb cannot cause one.

Kanna fits if

The acute, situational effect is what you are after, you take no serotonergic medication, and you will buy the standardized extract the trials actually used.

Ashwagandha vs Kanna: common questions

Is either ashwagandha or kanna FDA-approved?
No. Ashwagandha is sold as an herbal supplement. Kanna is sold without a prescription as a mood supplement.
Which has stronger human evidence, ashwagandha or kanna?
Neither clearly. Both have human clinical data. The key source for ashwagandha is RCT, Indian J Psychol Med 2012; for kanna, it is Amygdala fMRI RCT, Neuropsychopharmacology 2013.
What are the main safety concerns with ashwagandha and kanna?
For ashwagandha, watch for rare but documented liver injury, usually 2 to 12 weeks after starting. For kanna, watch for serotonin toxicity risk when combined with SSRIs, SNRIs, MAOIs or other serotonergic drugs.

Key studies behind each

Ashwagandha

  1. Chandrasekhar K, Kapoor J, Anishetty S. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. PubMed 23439798
  2. Lopresti AL, Smith SJ, Malvi H, Kodgule R. (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). PubMed 31517876
  3. Salve J, Pate S, Debnath K, Langade D. (2019). Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: A double-blind, randomized, placebo-controlled clinical study. Cureus. PubMed 32021735
  4. Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. (2019). Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study. Cureus. PubMed 31728244

Kanna

  1. Terburg D, Syal S, Rosenberger LA, Heany S, Phillips N, Gericke N, Stein DJ, van Honk J. (2013). Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology. PubMed 23903032
  2. Reay J, Wetherell MA, Morton E, Lillis J, Badmaev V. (2020). Sceletium tortuosum (Zembrin) ameliorates experimentally induced anxiety in healthy volunteers. Hum Psychopharmacol. PubMed 32761980
  3. Chiu S, Gericke N, Farina-Woodbury M, Badmaev V, Raheb H, et al. (2014). Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects. Evid Based Complement Alternat Med. PubMed 25389443
  4. de Jong M, van Niekerk S, Hamman J, van der Kooy F. (2026). Mesembryanthemum tortuosum and Zembrin: Mixed Evidence from In vivo Animal and Clinical Studies on their Antidepressant and Anxiolytic Effects. Planta Med. PubMed 41771298

The full evidence reviews

  • Ashwagandha: what the evidence actually shows for stress, sleep, and testosterone

    The most-studied adaptogen has genuinely strong RCT evidence for lowering stress and cortisol, decent data for anxiety and sleep, and a modest testosterone signal — plus a rare-but-real liver-injury caveat.

    Updated August 2026

  • Kanna: an SSRI-like mechanism sold as a mood supplement

    Kanna's researched extract is a dual serotonin-reuptake and PDE4 inhibitor — the same target class as an antidepressant — yet nearly all of its human evidence belongs to one branded product, the best anxiety trial ran two studies of which the first was null, and a 2026 review calls the literature mixed.

    Updated August 2026

Related comparisons